Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 3, 2020
Daily News
June 3, 2020
- Lilly Expects Topline Data for 2 COVID-19 Drug Candidates by June-End, First Patient Dosed in Antibody Treatment Study: Japan Execs
June 3, 2020
- Japan Eyes Coronavirus Vaccination Launch in First Half of 2021
June 3, 2020
- Shionogi Aims at 500 Billion Yen Sales in FY2024: New 5-Year Plan
June 3, 2020
- Kyowa Hakko Bio’s GMP Breach Triggers Shipment Curbs, Stockouts at Astellas, Kowa; Impact Could Reverberate Further
June 3, 2020
- Asahi Kasei Pharma Grabs China Approval for Flivas
June 3, 2020
- Eisai’s Insomnia Med Dayvigo Now Available in US
June 3, 2020
- Fetroja Gets FDA’s Priority Review for Nosocomial Pneumonia
June 3, 2020
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
- Label Updates Ordered for Uptravi, Plavix, Permitting Their Concomitant Use: MHLW
June 3, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…